Nifedipine Pharmacology and Dosing
Nifedipine is a dihydropyridine calcium channel blocker that selectively inhibits calcium influx into vascular smooth muscle, causing peripheral arterial vasodilation and blood pressure reduction without significant cardiac conduction effects at therapeutic doses.
Mechanism of Action
Nifedipine works by blocking voltage-dependent calcium channels in vascular smooth muscle, preventing calcium influx required for muscle contraction 1. This results in:
- Peripheral arterial vasodilation with reduced peripheral vascular resistance
- Decreased afterload and myocardial oxygen demand
- Minimal direct cardiac effects on contractility or conduction (unlike non-dihydropyridines like diltiazem or verapamil)
The drug does not alter serum calcium concentrations and acts primarily on vascular smooth muscle rather than cardiac tissue 1.
Pharmacokinetics
Absorption and Bioavailability
- Immediate-release formulation: Rapid absorption with peak plasma concentration at 0.7 hours (196 ng/mL), elimination half-life of 2 hours 2
- Extended-release (GITS) formulation: Delayed absorption with 2-3 hour lag time, peak at 2.5-5 hours (with second peak at 6-12 hours), elimination half-life of 7 hours 1
- Bioavailability of extended-release is 84-89% relative to immediate-release 1
Metabolism and Excretion
- Extensively metabolized via cytochrome P450 3A4 to inactive water-soluble metabolites 1
- 60-80% excreted in urine as metabolites; remainder in feces
- High protein binding (92-98%) 1
- Avoid grapefruit juice which inhibits CYP3A4 and increases drug levels 1
Special Populations
- Hepatic impairment: Longer half-life and higher bioavailability; use with caution 1
- Renal disease: Absorption may be modified; exercise caution 1
- Pregnancy: Crosses placenta; metabolism may increase during pregnancy 3
Dosage Recommendations
Hypertension (General Adult Population)
Extended-Release Formulation (Preferred) 1, 4:
- Starting dose: 30 mg once daily on an empty stomach
- Titration: Increase over 7-14 days based on response
- Usual maintenance: 30-60 mg once daily
- Maximum: 90 mg once daily (doses above 90 mg not recommended)
- Administration: Swallow whole; do NOT bite, chew, or divide tablets
Important: The 2018 ACC/AHA guidelines list nifedipine long-acting at 30-90 mg once daily as a standard antihypertensive option 4. Extended-release formulations provide full 24-hour coverage and are preferred over immediate-release.
Hypertensive Emergencies
Immediate-release nifedipine has a BLACK BOX WARNING and should generally be avoided in acute settings due to risks of excessive hypotension, myocardial infarction, stroke, and arrhythmias 5, 6. However, specific contexts exist:
- Dose: 10-20 mg orally (NOT sublingual—this route is not FDA-approved)
- Onset: 10-20 minutes (oral), peak effect 30-60 minutes
- Duration: 4-6 hours
- Expected reduction: Mean arterial pressure decreases approximately 21.6% (from ~248/134 to ~165/87 mmHg)
Critical caveat: A 2023 study found 27% of critically ill patients experienced clinically significant hypotension with immediate-release nifedipine, and 4% required vasopressor initiation 6. Intravenous agents (nicardipine, clevidipine) are strongly preferred for hypertensive emergencies 4.
Pregnancy-Related Hypertension
Nifedipine (extended-release) is a first-line agent for hypertension in pregnancy 9, 10:
Chronic hypertension in pregnancy 10:
- Goal BP: <140/90 mmHg
- Typical dosing: 30-60 mg once daily (extended-release)
- A 2024 study showed no difference in efficacy between 30 mg BID vs 60 mg QD, suggesting once-daily dosing is reasonable for convenience 3
Severe hypertension (≥160/110 mmHg) 9:
- Immediate-release: 10-20 mg orally, repeat in 20 minutes if needed
- Maintenance: 10-20 mg every 2-6 hours; maximum 180 mg/day
- Onset: 5-10 minutes
- Goal: Reduce BP to <160/<110 mmHg within 30-60 minutes
Contraindications in pregnancy 9, 10:
- ACE inhibitors, ARBs, direct renin inhibitors, atenolol, spironolactone, and nitroprusside are contraindicated
- Nifedipine is preferred over these agents
Acute Coronary Syndromes
Immediate-release nifedipine is CONTRAINDICATED in NSTE-ACS without concurrent beta-blocker therapy (Class III: Harm) 5, 11. The HINT trial was stopped early due to harm with nifedipine monotherapy 11, 12.
If calcium channel blocker needed 5:
- Use non-dihydropyridines (diltiazem or verapamil) instead
- Only if beta-blockers contraindicated AND no LV dysfunction
- Nifedipine may be added to existing beta-blocker therapy if needed for refractory ischemia
Common Side Effects
Dihydropyridine-specific effects 11, 12, 13:
- Peripheral edema (dose-related, more common in women)
- Headache
- Flushing
- Dizziness
- Hypotension (especially with immediate-release)
- Reflex tachycardia (less common with extended-release)
Serious adverse events (primarily with immediate-release) 6:
- Excessive hypotension requiring vasopressors (4%)
- New-onset arrhythmias (16%)
- Myocardial injury (18%)
Critical Clinical Pitfalls
Formulation confusion: Extended-release and immediate-release are NOT interchangeable. Always verify which formulation is prescribed 1, 2.
Food effects: High-fat meals increase peak concentration by 60% with extended-release formulations; administer on empty stomach 1.
Drug interactions: CYP3A4 inhibitors (ketoconazole, grapefruit juice) significantly increase nifedipine levels 1.
Acute coronary syndromes: Never use immediate-release nifedipine without beta-blocker coverage 5.
Anesthesia risk: Consider discontinuing nifedipine before surgery in elderly patients or those with cardiac abnormalities, as it may potentiate anesthetic-induced bradycardia and hypotension 14.
Heart failure: Avoid in patients with HFrEF; amlodipine or felodipine are better tolerated if a dihydropyridine is required 4.
Bedtime dosing advantage: For extended-release formulations, bedtime administration provides twice the efficacy at 60 mg dose and reduces adverse events by 74% compared to morning dosing 15.